Articles On Alchemia (ASX:ACL)

Healius gets takeover offer from ALC, a company more than half its size Neurotech will launch Phase 2 clinical trial in Rett Syndrome Germany allows Invex to commence the IIH EVOLVE Phase 3 clinical trial   Healius gets takeover offer fro...

The Healius Ltd (ASX: HLS) share price has jumped after receiving a takeover offer from Australian Clinical Labs Limited (ASX: ACL). Healius and ACL are two of the largest pathology businesses in Australia. Merger offer ACL announced this m...

The Australian Clinical Labs Ltd (ASX: ACL) share price is having a solid start to the week. In morning trade, the ASX All Ords healthcare share is up 3% to $3.73. Why is the ASX All Ords healthcare share rising? The catalyst for this has...

The Healius Ltd (ASX: HLS) share price is defying the market weakness and pushing higher on Monday. At the time of writing, the healthcare company’s shares are up 7% to $2.97. Why is the Healius share price pushing higher? Investors have...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

With much uncertainty hanging over both consumers and businesses, stock picking at the moment is a fraught activity. However, there could be a pretty straightforward method to spot ASX shares worthy of buying. Some stocks took off during l...

The end of the week is drawing near, and with it comes a massive day for ASX shares and their earnings. Some of the largest companies across healthcare, industrials, and utilities are reporting their latest figures. Which will be showered...

ShareCafe3 Small Caps Set for Long-Term Success by Simon Conn and Marc Whittaker   Calendar year 2022 was a difficult one for investors in the small cap sector of the market – with the ASX Small Ordinaries index falling -20.4% over the year...

Although — or maybe because — small-cap ASX shares were absolutely hammered in 2022, some experts are tipping a roaring comeback in 2023. IML portfolio managers Simon Conn and Marc Whittaker are certainly in this camp and specifically like...

If you want to buy a car, you try to look for the best price.  Who in their right mind would want to pay $50,000 if they can purchase the same vehicle for $40,000? So it’s irrational when investors are put off by ASX shares that have recen...

S&P/ASX 200 Index (ASX: XJO) healthcare shares saw a very mixed performance during the COVID-19 years of 2021 and 2022. But will 2023 be a stronger year? For a few names, the pandemic saw elevated earnings. COVID testing produced a lot...

Sure, it’s been a frightening time for investors. But 2022 has also been an opportunity to pick up some absolute bargains as quality ASX shares end up heavily discounted. With this in mind, it’s prudent to see which stocks have fallen rad...

The ASX is up 0.50% with Energy leading the way Energy stocks gain as coal plays led again The European Central Bank (ECB) will announce its rates decision today   Aussie shares rose half a percent on Thursday to a 6-week high, with all s...

Highlights The S&P/ASX 200 closed marginally up on Thursday (27 October 2022), gaining 41.40 points or 0.61% to close at 6,852.30 points. Nine out of eleven sectors ended higher. Energy sector lead the gains as it closed 2.34% up,...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. At the time of writing, the benchmark index is up 0.55% to 6,847.4 points. Four ASX shares that have failed to follow the market higher today ar...

The Australian Clinical Labs Ltd (ASX: ACL) share price is crashing deep into the red on Thursday. In morning trade, the pathology services provider’s shares are down 12% to $3.12. Why is the Australian Clinical Labs share price sinking?...

Australian Clinical Labs (ASX: ACL) owned Medlab Pathology has joined a growing list of companies impacted by cyber attacks after revealing a data breach has affected the health records and credit card information of almost 223,000 people,...

ShareCafeUS markets rise as EV battery integration grows rapidly under Biden Administration                    US equities were mostly higher in fairly choppy Wednesday trading. The Nasdaq Composite ground higher in choppy trading on...

When investing in times of economic uncertainty like now, it can help to think of the brands you use on a day-to-day basis. If you and millions of Australians are already regularly using the products and services, that demand may well rema...

With ASX reporting season in full swing, S&P/ASX 200 Index (ASX: XJO) shares are declaring dividends left, right, and centre. Once dividends are declared, there’s a cut-off date to determine which shareholders are entitled to the upc...

We’re well and truly in the thick of ASX reporting season. The biggest names in the All Ordinaries Index (ASX: XAO) are unveiling their financial results. And many are declaring lucrative dividends. With that comes an important date: the...

ShareCafeEnergy crisis playing out across the globe                    US equities finished lower in Monday trading, ending near the worst levels. Investors are anticipating what could be a volatile week of trading ahead of Federal Re...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is a sea of red and down heavily. At the time of writing, the benchmark index is down 4.25% to 6,634.7 points. Four ASX shares that have defied the odds and pushed higher are listed...

Highlights XAO or All Ords entails the 500 largest companies on the ASX XAO is down by nearly 5.19% on a YTD basis, as of 7 June 2022 The healthcare space has witnessed great developments amid the COVID-19 outbreak. The All Ordina...

IDX snaps up QLD-based radiology group for circa $38m  NSB starts HREC review process  Credit Suisse downgrades HLS, initiates coverage of ACL   Integral Diagnostics Limited (ASX:IDX) says it’s agreed to terms with Queensland-based Exact...

In what can only be described as a remarkable turnaround, the Aussie sharemarket is closing in on breakeven for 2022, with the S&P/ASX 200 (ASX: XJO) gaining another 0.7% on Wednesday. A positive lead from the US and signs of a ceasefir...

The federal budget has, understandably, been the talk of the town today, with many market watchers questioning which shares will be budget winners and which might be less fortunate. And while ASX stocks in the retail, fuel, and automotive...

Highlights Stock exchange rules determine the ex-dividend date once the corporation sets the record date. A record date is a date by which an investor must be listed as a shareholder on the company's books. An investor will get the di...

The Australian Clinical Labs Ltd (ASX: ACL) share price dropped with the market on Thursday despite the release of a strong half year update from the pathology company. The company’s shares ended the day 3.5% lower at $4.85. Australian Cli...

Australian Clinical Labs (ASX: ACL) has been collecting both swabs and earnings as a wave of COVID-19 testing propped up revenue by 61.2 per cent in the December half, reaching $538 million and thus surpassing its entire revenue for FY20....

Key points The benchmark index has started the year well after a choppy period these past few months The team at RBC Capital Markets reckon these three ASX shares are poised to deliver upside in 2022 Analysts at the firm recently upgraded...

There are a few S&P/ASX 200 Index (ASX: XJO) shares that are making a lot of revenue and profit from the high level of COVID-19 testing. A few key providers are providing millions of tests, such as Sonic Healthcare Ltd (ASX: SHL) and H...

Returns in the ASX healthcare basket were fairly robust throughout 2021. Sector earnings saw a return to pre-COVID levels as patient and service volumes began to normalise as well. The S&P/ASX 200 Health Care Index (ASX: XHJ) has clim...

ASX investors evidently shrugged off omicron fears in December, with the last month of the 2021 being the second best of the year. Ultimately, the market finished 2021 13% higher than it started. Patience pays off, unless you got in at the...

The Australian Clinical Labs Ltd (ASX: ACL) share price is tumbling today, but it’s had a whopping run lately. At the time of writing, the Australian Clinical Labs share price is $5.87. That’s 1.51% lower than its previous close but 38% hi...

It has been another busy week for Australia’s top brokers. This has led to the release of a large number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these...

Wall Street rallies as sentiment lifts US and European stock markets finally rose overnight after three days of losses. The global rebound followed more developments on the omicron front, as British PM Boris Johnson ruled out any lockdown b...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.75% to 7,346.6 points. Four ASX shares that are climbing more than most today are listed bel...

The Australian Clinical Labs Ltd (ASX: ACL) share price is up more than 5% today to $5.26 after the business upgraded first-half guidance expectations. The company operates 86 laboratories across Australia, providing pathology services incl...

The arrival of omicron in Australia has led to COVID test volumes spiking again and Australian Clinical Labs (ASX:ACL) is one of the companies benefiting. This morning the company upgraded its guidance for the first half of FY22 for the sec...

21 Dec 2021 - A snapshot of the stocks on the move featuring AMP (ASX:AMP), Magellan Financial (ASX:MFG), and Australian Clinical Labs (ASX:ACL).

21 Dec 2021 - Australian Clinical Labs (ASX:ACL) has upgraded its earnings and revenue forecast for the first half of FY22, underpinned by strong demand for Covid-19 testing.

The Australian Clinical Labs Ltd (ASX: ACL) share price has hit a record high on Tuesday morning. At the time of writing, the pathology services provider’s shares are up 10% to $5.47. Why is the Australian Clinical Labs share price chargin...

Wall Street falls amid Omicron uncertainty The US stock markets fell for the third consecutive day, as the S&P 500 had its biggest three day drop since September. All three major benchmarks fell – the S&P 500 by 1.14%, the Dow Jones...

Australian Clinical Labs (ACL) acquires Medlab Pathology, who own laboratories and collection centres across New South Wales (NSW) and Queensland (QLD) The $70 million acquisition allows the deliverance of a doubling of market share to 20....

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) looks set to start the week with a decline. At the time of writing, the benchmark index is down 0.3% to 7,280.8 points. Four ASX shares that have not let that hold them back are list...

The ASX 200 Health Index (XHJ) is trading higher by 0.92% at the time of writing, compared to the broader index which is down by 0.22%. Cannabis-based medtech company, Emyria Limited (ASX:EMD), has signed an agreement with Seattle-based Cyd...

If you’re interested in adding some small caps to your portfolio, then you may want to check out the ones listed below. These small cap shares are rated highly by analysts and have been given buy ratings recently. Here’s what you need to k...

The PolyNovo Ltd (ASX: PNV) share price has been under pressure in recent weeks. Since the beginning of November, the burns treatment specialist has fallen nearly 24% in value. Meanwhile, the overall healthcare sector has gained 1.4% durin...

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index which is up by 0.40%. Mesoblast (ASX:MSB) jumped 10% after reporting data from its Phase 3 trial of rexlemestrocel-L in chronic heart failure...